Evidence map›Paper›PMID 32816577›Full record

ArticlemAbs

AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design.

Mario Sanches, Igor D'Angelo, Maria Jaramillo, Jason Baardsnes, John Zwaagstra, Joe Schrag, Ian Schoenhofen, Mauro Acchione, Sam Lawn, Grant Wickman and 4 more

Abstract readVideo-Audio Media
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Albumin as a Biomaterial and Therapeutic Agent in Regenerative Medicine.International journal of molecular sciences · 2022
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mario SanchesR&D, Zymeworks Inc , Vancouver, BC, Canada.
Igor D'AngeloOne Amgen Center Dr, Amgen Inc ., Thousand Oaks, CA, USA.
Maria JaramilloHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.ORCID 0000-0002-2416-9009
Jason BaardsnesHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.ORCID 0000-0001-5587-3034
John ZwaagstraHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.
Joe SchragHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.
Ian SchoenhofenHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.
Mauro AcchioneHuman Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada.
Sam LawnR&D, Zymeworks Inc , Vancouver, BC, Canada.
Grant WickmanR&D, Zymeworks Inc , Vancouver, BC, Canada.
Nina WeisserR&D, Zymeworks Inc , Vancouver, BC, Canada.
David K Y PoonR&D, Zymeworks Inc , Vancouver, BC, Canada.
Gordon NgSearch and Evaluation, Abbvie Inc , North Chicago, Illinois, USA.
Surjit DixitR&D, Zymeworks Inc , Vancouver, BC, Canada.ORCID 0000-0003-0197-1629

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the preferred scaffold for biologics development while there has been limited exploration into the use of albumin with its unique physiological characteristics as a platform for biologics design. There has been a great deal of interest to create bispecific and more complex multivalent molecules to build on the advantages offered by protein-based therapeutics relative to small molecules. Here, we explore the use of human serum albumin (HSA) as a scaffold for the design of multispecific biologics. In particular, we describe a structure-guided approach to the design of split HSA molecules we refer to as AlbuCORE, that effectively and spontaneously forms a native albumin-like molecule, but in a heterodimeric state upon co-expression. We show that the split AlbuCORE designs allow the creation of novel fusion entities with unique alternate geometries. We also show that, apart from these AlbuCORE fusion entities, there is an opportunity to explore their albumin-like small hydrophobic molecule carrying capacity as a drug conjugate in these designs.

Indexed as

Protein EngineeringProtein MultimerizationHumansHydrophobic and Hydrophilic InteractionsSerum Albumin, HumanSerum Albumin, HumanAlbuCOREAlbuminbiologicsdrug conjugateHSAHuman serum albuminmultispecificmultivalentnon-antibody scaffoldtherapeutic scaffold

Identifiers

PMID32816577
PMCPMC7531512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.